Wegovy Heart Benefits: Evidence and NICE Guidance

Last updated: 13 October 2026

What Are the Heart Benefits of Wegovy?

Wegovy has been shown to reduce the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in a specific group of adults who already had cardiovascular disease and were living with overweight or obesity. In the SELECT trial, these events occurred in 6.5% of people given semaglutide and 8.0% of those given a placebo, which was a 20% relative reduction in risk.

This evidence does not mean Wegovy prevents heart disease in everyone who wants to lose weight. The trial involved adults aged 45 or over with a BMI of at least 27 and established cardiovascular disease, but without diabetes. Wegovy must still be used alongside standard cardiovascular treatment and prescribed after an individual clinical assessment.

Key Points

The strongest evidence relates to people who already have cardiovascular disease, rather than people at low risk.
SELECT studied 17,604 adults aged 45 or over with a BMI of at least 27 and no diabetes.
The combined risk of cardiovascular death, non-fatal heart attack or non-fatal stroke fell from 8.0% with placebo to 6.5% with semaglutide.
The 20% figure is a relative risk reduction. The absolute difference between the groups was 1.5 percentage points.
Wegovy does not replace statins, blood-pressure medicines, antiplatelet treatment or lifestyle advice.
Suitability and NHS access depend on an individual assessment and the relevant local treatment pathway.

Wegovy Heart Benefits Explained

When patients ask me whether Wegovy is good for the heart, I explain that there are two separate ideas to understand. Losing excess weight can improve factors linked with cardiovascular health, such as blood pressure and waist measurement. There is also direct trial evidence that semaglutide reduced major cardiovascular events in people who already had cardiovascular disease.

The UK cardiovascular indication covers adults with established cardiovascular disease and overweight or obesity. It is used with a reduced-calorie diet and increased physical activity. It is not a general heart-protection medicine for everyone, and it does not replace the treatment already prescribed by a GP or cardiology team.

The Wegovy injection contains semaglutide, a GLP-1 receptor agonist. Its suitability depends on your health, medicines, treatment goals and risk of side effects.

Key takeaway: Wegovy has a licensed cardiovascular indication, but the evidence concerns people with established cardiovascular disease and overweight or obesity. It should not be described as a universal way to prevent heart disease.

What Did the SELECT Trial Find?

SELECT was a large randomised trial involving 17,604 adults. Participants received semaglutide 2.4 mg once weekly or a placebo alongside their usual care. They were followed for an average of about 40 months.

The main outcome combined three serious events: death from cardiovascular causes, a non-fatal heart attack and a non-fatal stroke. At least one of these events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group.

SELECT finding	Result	What it means
Semaglutide group	6.5% had a major cardiovascular event	569 of 8,803 participants
Placebo group	8.0% had a major cardiovascular event	701 of 8,801 participants
Relative risk reduction	20%	The risk was one fifth lower relative to placebo
Absolute difference	1.5 percentage points	The difference between 8.0% and 6.5%

Both figures matter. The 20% relative reduction describes the proportional difference between the groups. The 1.5 percentage-point absolute difference shows how often the outcome actually occurred during the trial. Neither figure can predict what will happen to an individual patient.

The cardiovascular result is one part of a wider picture. The benefits of weight loss injections may also include changes in blood glucose, blood pressure, waist measurement and daily functioning, depending on the medicine and the person being treated.

Key takeaway: SELECT provides strong evidence of cardiovascular benefit in the population studied. The result was meaningful, but it should be presented with both the relative and absolute figures.

Who Do the Wegovy Heart Benefits Apply To?

SELECT did not recruit a general weight-loss population. Participants were aged 45 or over, had a BMI of at least 27 and already had cardiovascular disease. This included people with a previous heart attack or stroke, or symptomatic peripheral arterial disease. The trial excluded people with diabetes.

The UK cardiovascular indication is for adults with established cardiovascular disease and overweight or obesity. However, the details of the trial still matter when interpreting the size of the benefit. Results from a high-risk group should not be used to promise the same effect to a younger person with no history of cardiovascular disease.

Meeting a BMI or medical-history criterion does not make treatment automatic. A clinician must review other medicines, previous side effects, pregnancy plans, gallbladder and pancreatic history, kidney health and any condition that may make treatment unsuitable.

What Does NICE Say About Wegovy and Heart Health?

NICE technology appraisal TA1152 recommends semaglutide as an option for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. It is secondary prevention, which means trying to prevent another serious event in someone who already has cardiovascular disease.

The recommendation places semaglutide alongside existing cardiovascular treatment, a reduced-calorie diet and increased physical activity. NHS availability still depends on a clinical assessment and the pathway used by the local service. If you think the guidance may apply to you, speak to your GP or cardiovascular team rather than stopping or changing your current medicines.

Key takeaway: The NICE recommendation is about preventing further cardiovascular events in people with established disease. Local access and individual suitability still need to be assessed.

Does Wegovy Protect the Heart If You Do Not Have Cardiovascular Disease?

SELECT cannot answer that question because every participant already had cardiovascular disease. Weight loss may improve several risk factors, but that is different from proving that Wegovy prevents a first heart attack or stroke in someone without established disease.

If Wegovy is prescribed for weight management, the decision should be based on the licensed weight-management criteria and your overall health. Potential cardiovascular benefits should not be used as a guarantee or as a reason to overlook cost, side effects and the practical commitment of longer-term treatment. Our guide on whether Wegovy is worth it considers those wider factors.

How Does Wegovy Fit With Other Heart Treatment?

Wegovy is an addition to standard care, not a replacement for it. Depending on your condition, standard care may include a statin, blood-pressure treatment, antiplatelet medicine, support to stop smoking, rehabilitation and advice about food and activity.

Tell the prescribing clinician about every medicine you take and every team involved in your care. A reduced appetite, vomiting or diarrhoea can affect hydration and may be especially important if you take diuretics or medicines that affect kidney function. Our guide to Wegovy side effects explains common symptoms and the signs that need medical advice.

Seek urgent help for symptoms of a possible heart attack or stroke, such as sudden chest pain, severe breathlessness, facial weakness, arm weakness or speech difficulty. Do not assume a new symptom is caused by Wegovy and wait for it to settle.

Summary: Wegovy Heart Benefits

Wegovy has evidence for reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. The claim needs to remain tied to the population studied and the treatment context.

SELECT studied 17,604 adults aged 45 or over with established cardiovascular disease, BMI of at least 27 and no diabetes.
Major cardiovascular events occurred in 6.5% with semaglutide and 8.0% with placebo.
This represents a 20% relative reduction and a 1.5 percentage-point absolute difference.
NICE recommends semaglutide as an option for secondary cardiovascular prevention in eligible adults.
Wegovy should be used alongside established cardiovascular treatment and clinical follow-up.
The evidence does not prove that Wegovy prevents a first cardiovascular event in everyone using it for weight loss.

Frequently Asked Questions

Is Wegovy good for your heart?

Wegovy reduced major cardiovascular events in SELECT, which studied adults with established cardiovascular disease and overweight or obesity but no diabetes. This does not show that everyone taking Wegovy will receive the same heart benefit.

How much did Wegovy reduce cardiovascular risk?

The combined risk of cardiovascular death, non-fatal heart attack or non-fatal stroke was 20% lower relative to placebo. Events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group, an absolute difference of 1.5 percentage points.

Can Wegovy prevent a first heart attack?

SELECT did not test Wegovy for preventing a first cardiovascular event in people without established cardiovascular disease. Its results should not be extended beyond the population studied.

Can Wegovy replace statins or blood-pressure medicine?

No. Wegovy was studied alongside standard cardiovascular care. Do not stop or change statins, blood-pressure medicines, antiplatelet treatment or any other prescribed medicine without speaking to your clinician.

Can you get Wegovy on the NHS for cardiovascular risk?

NICE recommends semaglutide as an option for eligible adults with established cardiovascular disease and overweight or obesity. Access still requires an individual assessment and depends on how the relevant NHS service is delivered locally.

Does the heart benefit come only from weight loss?

SELECT showed cardiovascular benefit, but the trial was not designed to give a simple answer about how much came from weight loss or other effects of semaglutide. It is safer to describe the trial result than to claim one proven mechanism.

A Note from Our Pharmacist

Palvinder Deol, Superintendent Pharmacist, Happy Pharmacy

I would be cautious about describing Wegovy as a medicine that simply “saves hearts”. The SELECT result is important, but it came from people who were already at high cardiovascular risk. That context changes how the numbers should be understood.

When I discuss treatment with a patient who has cardiovascular disease, I want to know what their GP or cardiology team has prescribed, whether their blood pressure is stable and how they are managing food and fluid. Wegovy has to fit safely around that existing care.

My practical message is to treat the cardiovascular evidence as an additional potential benefit for the right patient. It is not a reason to stop proven heart medicines or to assume that a prescription is automatically suitable.

Considering Wegovy Treatment?

Complete our secure online consultation. Our pharmacy team will review your answers, medical history and current medicines before advising whether treatment is suitable.

View Wegovy Treatment >

References

NICE TA1152. Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity. Read the NICE guidance.
Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023. Read the SELECT trial.
MHRA. Semaglutide approved to reduce the risk of serious heart problems in adults with established cardiovascular disease and overweight or obesity. Read the MHRA announcement.
Wegovy Summary of Product Characteristics. Current UK prescribing information for semaglutide. Read the eMC prescribing information.